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After the publication of the original article \[[@CR1]\], we were notified the upper panel of the Fig. 1, where the patients' codes are listed, was cropped by mistake so the patients 1--8 are repeated. The 88 patients should be listed, instead.

Below is the correct version of Fig. [1](#Fig1){ref-type="fig"}. Fig. 1*ESR1* mutation analysis in the metastatic cohort and its clinical significance. **a** Analysis of matched samples from the metastatic cohort through the course of disease: primary tumor, newly diagnosed metastases, and advanced metastases. Samples are colored according to their mutation type. Red indicates *ESR1* Mut. Green indicates *ESR1* WT. *ESR1* mutations at an allele frequency of \> 1% are marked by an asterisk. Dark gray indicates that a tumor was present at this time point but a sample was not available. Lower bars represent the treatments given for each patient pre-biopsy, either at the adjuvant phase before the metastatic disease or at the advanced phase before the advanced metastatic biopsy. TAM, tamoxifen, light blue; AI, aromatase inhibitor, blue. **b** Prevalence of *ESR1* mutations divided according to the metastatic disease stage and the type of treatment prior to biopsy. **c** Kaplan-Meier plots of progression-free survival calculated from the start of AI treatment at the metastatic setting
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